Pancreatic Cancer Drug Daraxonrasib Wins FDA Nod With Broad Label

A pill that doubled survival is now on the market

The FDA approved Rasonque (daraxonrasib) on August 26, 2026. It is a once-daily tablet that targets several forms of RAS, the protein that drives tumor growth in most cases of pancreatic adenocarcinoma, which is the most common type of pancreatic cancer.13 Revolution Medicines developed the drug. It is approved for adults with metastatic pancreatic adenocarcinoma who have had at least one earlier systemic treatment, and for those who cannot receive multiagent systemic therapy.1019 The agency called it the first targeted therapy of its kind for metastatic pancreatic cancer.13

Six weeks on, coverage still describes the approval as a turning point. In this case the description holds up. The trial result was large, the review was unusually fast, and the label is wider than the trial population. Each of these deserves a closer look, and together they suggest the approval will matter well beyond second-line pancreatic cancer.

What the RASolute 302 data showed

The approval rests on RASolute 302, a phase 3 trial of 500 adults with metastatic pancreatic ductal adenocarcinoma. Every patient had already received one regimen built on fluoropyrimidine or gemcitabine. Half were randomized to 300 mg of daraxonrasib daily (248 patients) and half to one of four chemotherapy regimens chosen by their doctors (252 patients).4 The trial ran at 59 sites in six countries.16

The headline finding is overall survival. In the primary group of patients with RAS G12 mutations, median survival was 13.2 months on daraxonrasib versus 6.6 months on chemotherapy, with a hazard ratio of 0.40.4 Across all enrolled patients, including those without an identified RAS mutation, the figures were 13.2 versus 6.7 months, with the same hazard ratio.4 One patient-focused outlet put that as roughly a 60% lower risk of death.3

The secondary results point the same way. In the G12-mutant group, median progression-free survival by blinded independent review was 7.3 months versus 3.5 months. Confirmed objective response rates were 33.2% versus 11.8%.419 Patients on the drug also took longer to report worsening cancer-related pain (9.2 versus 3.8 months) and lower overall quality of life (5.7 versus 2.6 months).4 The results were presented in the plenary session of the 2026 ASCO Annual Meeting and published in the New England Journal of Medicine at the same time.4 ASCO leaders reportedly called them a "grand slam" from the stage.

Coverage generally treats tolerability as another point in the drug's favor, not a trade-off. Treatment-related adverse events led 1.2% of daraxonrasib patients to stop treatment, compared with 11.2% on chemotherapy.15 The FDA lists rash, nausea and abdominal pain as the most common side effects.2 Brian Wolpin of Dana-Farber, who led the trial, has said patients in the study had fewer side effects overall on the drug than on chemotherapy.17

Why RAS matters

The scientific weight of the approval comes from the target. RAS mutations drive most pancreatic cancers, and RAS was long considered "undruggable."3 One trial-tracking analysis puts the share of KRAS-driven pancreatic tumors at about 90%. It also notes that second-line chemotherapy has typically given patients only six to seven months of median survival.

Earlier KRAS inhibitors were each built to block a single mutation. Daraxonrasib works differently: it is a tri-complex inhibitor that binds cyclophilin A inside the cell and then blocks active, GTP-bound RAS from signaling. That covers G12, G13 and Q61 variants as well as normal (wild-type) RAS.4 This breadth matters in pancreatic cancer, where several different KRAS variants are common. A drug aimed at one variant would leave many patients without a matching target.10

The trial is described as the first positive phase 3 study of any RAS-targeted therapy in pancreatic cancer. Wolpin called the results the biggest therapeutic advance in metastatic pancreatic cancer in decades.17 Jonathan Mizrahi, an oncologist at Ochsner MD Anderson, made the same point more plainly: the field had never had an oral targeted pill for this disease, or anything in this setting that doubled survival.2

A broad label

The label is the most consequential part of the approval, and the one most likely to be underestimated. The trial required documented RAS status, but the FDA did not require a known RAS mutation for patients to qualify.15 Investigators at the University of Miami's Sylvester Comprehensive Cancer Center said the approval was wider than they had expected.16 According to the prescribing information, there is no RAS-testing requirement and no companion diagnostic.

The FDA's reasoning is clear from the data. The survival benefit in the overall population matched the benefit in the G12-mutant group, so restricting the drug by genotype would have been hard to justify.415 One physician noted on the day of approval that the label skips KRAS documentation because about 95% of pancreatic cancers carry a mutation anyway.

The same physician also pointed to the word "or" in the indication. Because the drug is approved for previously treated patients or for patients who cannot tolerate multiagent therapy, he argued, the label could open a "soft" path into first-line use. That reading looks reasonable. Some patients unfit for aggressive combination chemotherapy may get the drug as their first treatment, before any formal first-line trial reports. Doctors will effectively be making that decision before the evidence for first-line use exists.

Speed of review, and where accounts differ

Reports agree that the approval came 6.5 months ahead of the user-fee deadline. They also agree it went through the FDA Commissioner's National Priority Voucher program, a pilot launched under former Commissioner Marty Makary.14 The drug also had Breakthrough Therapy designation, which it received in June 2025, plus Orphan Drug designation and Priority Review.113

Accounts of how long the review took do not line up. ABC News reported that the voucher shortened the review from 12 months to 10.1 Other details in the coverage point to something much faster. CancerNetwork reported that the application was accepted on July 22, 2026, with an expected review time of one to two months.4 Approval followed about five weeks after acceptance. Given those dates, the shorter timeline looks more accurate. The 12-to-10-month framing appears to understate how far the voucher program compressed this review.

The approval followed a series of earlier regulatory steps. The FDA allowed an expanded access program for previously treated patients in May 2026.4 Europe's medicines regulator began a phased review in July. In August, the European Society for Medical Oncology issued a guideline update recommending the drug after chemotherapy fails in patients with RAS G12-mutated disease and good performance status.4 Acting FDA Commissioner Kyle Diamantas praised his staff's "fast, thorough review."4 Politically, the case gives the voucher program a strong early success to point to.

Coverage also differs on credit. One public-radio summary described the drug as developed by Dana-Farber.8 Dana-Farber's own release is more careful: it says the approval rests mainly on a trial Dana-Farber led.12 Other coverage names Revolution Medicines as the developer.10 The more accurate account is that the company created the molecule and academic investigators ran the trial that proved it worked.

Cost and access

Physicians have debated a reported list price of $39,800 per month, according to a trial-tracking site that collected their online reactions. None of the mainstream coverage addresses what that price will mean for insurers and patients. That gap is likely to become harder to ignore as use grows. With the label's possible reach into first-line use, the cost question could become larger, not smaller.

On access, health systems note that approval moves the drug out of trial enrollment and expanded-access programs and into routine prescribing.18 A New Orleans report said production is expected to increase quickly after approval.2 Patient groups say the approval has brought a wave of questions from the community.6

What comes next

The RASolute program is already testing the drug earlier in the disease. RASolute 303 compares daraxonrasib alone and combined with gemcitabine plus nab-paclitaxel against standard first-line chemotherapy. RASolute 304 compares the drug with observation in patients whose tumors have been surgically removed.4 The broader development program also includes metastatic RAS-mutant non-small cell lung cancer. The drug is designed with colorectal cancer in mind as well.14

The most likely outcome is that the August approval marks the start of daraxonrasib's role, not its limit. A median survival of 13.2 months is still short, and the drug does not make metastatic pancreatic cancer controllable.10 Even so, a once-undruggable target has now produced a survival benefit that clinicians, regulators and European guideline writers all accepted within about three months of the data being released. If the first-line and post-surgery trials succeed, pancreatic cancer care could shift from a chemotherapy-first approach to one built around RAS.